II) Paraffin embedded kidney slides from diabetics with diabetic nephropathy (n: 12), non-diabetic control (n: 6) with primary glomerulopathy as minimal change disease, and diabetic controls without diabetic nephropathy (n: 6), will be studied. Investigators will recruit patients with kidney biopsy indicated, and scheduled to be performed, by their medical doctors. After pathology diagnosis completion, some of the remnant paraffin embedded tissue will be used for this study. The role of proteins involved in diabetic nephropathy, VEGF signaling and tenascin will be studied by immunohistochemistry and proximity link assay. Urine and plasma will be collected prior to the kidney biopsy in order to measure protein concentration of potentially useful biomarkers of diabetic nephropathy; VEGF and tenascin levels will be quantified. Patients will be informed and signed consent will be required.